摘要:
Biomarkers for diagnosis and prognosis of prostate cancer are provided. The biomarkers are promoter sequences have altered methylation patterns relative to normal prostate tissue. Altered expression of DNA methyltransferases (DNMT) and proteins that interact with DNMT result in increased methylation at a subset of prostate tumor hypermethylation sites.
摘要:
The invention describes DNA copy number alterations (CNAs), identifiable by technologies such as array-based comparative genomic hybridization (array CGH) or fluorescence in situ hybridization (FISH), that define distinct genetic subtypes of prostate cancer, and are useful for improved prognostication and treatment stratification for patients with prostate cancer.